Ad
related to: which atorvastatin was recalled betterRanked at No. 20 on the 2020 Disruptor 50 list. - CNBC
Search results
Results from the WOW.Com Content Network
On 9 November 2012, Indian drugmaker Ranbaxy Laboratories Ltd. voluntarily recalled 10-, 20- and 40-mg doses of its generic version of atorvastatin in the United States. [ 133 ] [ 134 ] [ 135 ] The lots of atorvastatin, packaged in bottles of 90 and 500 tablets, were recalled due to possible contamination with very small glass particles similar ...
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).
A drug recall removes a prescription or over-the-counter drug from the market. Drug recalls in the United States are made by the FDA or the creators of the drug when certain criteria are met. When a drug recall is made, the drug is removed from the market and potential legal action can be taken depending on the severity of the drug recall.
Statins are linked to better health outcomes in older adults over the age of 70 with or without previous cardiovascular disease, a new study finds.
The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12] The manufacturer Pfizer reported sales of US$12.4 billion in 2008. [13] Patient compliance with statin usage is problematic despite robust evidence of the benefits. [14] [15]
The American Heart Association recently updated its risk equations for predicting the risk of cardiovascular disease events, which means that millions of Americans may soon no longer qualify for ...
Glenmark Laboratories recalled 114 batches of 750 mg Potassium Chloride Extended-Release Capsules in bottles of 100 (NDC No. 68462-357-01) and 500 (NDC No. 68462-357-05) capsules.
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]